FDA Approves Opdivo Qvantig for Subcutaneous Injection

The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...

DECEMBER 30, 2024

Subcutaneous Injection of Nivolumab on the Horizon

Patients and clinicians may have an injectable form of the immunotherapy Opdivo available in their future.

MAY 13, 2024

Choosing Later Lines Of mRCC Therapy A Mix of Art and Science

Pharmacists have many guideline-directed options for front-line treatment of metastatic renal cell carcinoma.

MAY 16, 2023

Double Checkpoint Inhibitors Plus TKI Improves Control of RCC

In patients with advanced renal cell carcinoma, the addition of the tyrosine kinase inhibitor cabozantinib ...

OCTOBER 3, 2022

FDA Approves Nivolumab-Cabozantinib as First-Line Treatment of Advanced RCC

The FDA approved nivolumab in combination with cabozantinib for the first-line treatment of patients with advanced ...

FEBRUARY 10, 2021

Trials Support ImmunoRx Combos for Advanced RCC

Combination treatment with pembrolizumab and axitinib is emerging as a new standard of care for first-line ...

OCTOBER 8, 2019

FDA Approves Bavencio With Inlyta for Patients With Advanced Renal Cell Carcinoma

Bavencio with Inlyta is the first FDA approval for an anti–PD-L1 therapy as part of a combination regimen for ...

MAY 16, 2019